Roche pushes ahead with late-comer strategy in obesity

The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.

By Amy Baxter • July 30, 2025

Biotech investing is down, but some VC firms are bucking the trend

Discipline is the name of the game after a glut of over-investing burst the biotech bubble.

By Alexandra Pecci • July 29, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Could bispecifics unseat Keytruda from its oncology throne?

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

By Kelly Bilodeau • July 28, 2025

From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

The studies are contributing preclinical advances for some of the world’s biggest blockbusters.

By Michael Gibney • July 25, 2025

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

By Alexandra Pecci • July 24, 2025

Who is Dr. George Tidmarsh, the new director of CDER?

Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

By Meagan Parrish and Michael Gibney • July 23, 2025

Closing the gap: How real-world data and artificial intelligence are reinventing the last mile of clinical research

Clinical trial delays are costly—here’s how RWD and AI are transforming recruitment and retention.

July 21, 2025

FDA invites more data from abroad — with a wary eye on China

The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.

By Amy Baxter • July 16, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.

By Jonathan Gardner • July 11, 2025

Early measles drug R&D kicks into gear as U.S. records record outbreak

Several companies have announced preclinical efforts to develop the first-ever measles treatment.

By Meagan Parrish • July 11, 2025

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

Simone Steiner recently joined the French company to set the stage for launch.  

By Amy Baxter • July 9, 2025

The MEK effect on cancer — a slow and steady approach to drug resistance

Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

By Kelly Bilodeau • July 8, 2025

GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down

As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

By Amy Baxter • July 7, 2025

Can China sustain a surge in oncology drug innovation?

The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.

By Kelly Bilodeau • July 2, 2025

AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

By Michael Gibney • July 1, 2025

A biopharma bolsters patient centricity and trial diversity goals through newly created role

Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

By Alexandra Pecci • July 1, 2025

Biopharma is on edge about NIH funding cuts and what the future holds for research

Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

By Michael Gibney • June 26, 2025

After myriad failures, a new wave of ALS drugs approaches

Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.

By Amy Baxter • June 25, 2025

How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

By Michael Gibney • June 24, 2025

Biotech’s turning point: for every challenge, an opportunity in disguise

As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.

By Michael Gibney • June 20, 2025

The former Wall Street analyst shaping Novartis’ big-picture strategy

Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

By Michael Gibney • June 10, 2025

The mindfulness of medicine development: How scientists are driving the next wave of medical innovations

For millions of patients, the development of a new treatment or vaccine can be life-changing.

June 9, 2025

With ADCs on the rise, drugmakers embrace a new oncology pillar

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

By Michael Gibney • June 6, 2025

How leading oncology drugmakers set the stage for future advances

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

By Michael Gibney • June 3, 2025

COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies. 

By Kelly Bilodeau • June 2, 2025